
Am I Suitable for Focal Therapy?
Focal therapy is suitable for men with localised prostate cancer (Gleason 6-7, ISUP Grade 1-3) where the tumour is visible on MRI and confined to the prostate, with PSA typically at 20 ng/mL or below. At The Focal Therapy Clinic, our GMC-registered consultant urologists assess every referral using multiparametric MRI and targeted biopsy to confirm suitability. In our experience with over 2,000 procedures, men who meet these criteria achieve 97% continence preservation and 90%+ sexual function maintenance (FTC audit, n=265). For treatment details, see our pages on HIFU treatment for prostate cancer and NanoKnife IRE treatment.
How Eligibility for Focal Therapy Is Determined
PSA (Prostate-Specific Antigen)
- PSA is a blood test used to help assess prostate cancer activity and whether disease appears localized.
- PSA is reviewed alongside MRI findings, biopsy results, and Gleason score to determine suitability.
Gleason Score
- The Gleason score measures how aggressive prostate cancer cells appear under a microscope.
- Higher Gleason scores may indicate more aggressive disease that could require whole-gland treatment instead of focal therapy.
Ideal patients for Focal Therapy
Recommendations about eligibility can be discussed with our expert team of consultants
Even if it’s not, they can talk you through your other treatment options so that you can make an informed decision about the next steps in your care.
Ideal patients for Focal Therapy
- Low-Risk and Intermediate-Risk Prostate Cancer
Patients with a Gleason score of 6 or 7, with grade group 1 to 3 cancers (which indicates less aggressive cancer) are the best candidates. - tumours Confined to the Prostate
The effectiveness of focal therapy depends on whether the cancer is restricted to one or a few distinct areas within the prostate. - PSA Levels Below a Certain Threshold
Candidates typically have a prostate-specific antigen (PSA) level of 20 ng/mL or lower. - No Evidence of Metastasis
Focal therapy is only suitable for patients whose cancer is localised and has not spread to lymph nodes, bones, or other distant areas. - Patients Seeking a Less Invasive Treatment
Men who prefer to avoid the potential side effects of surgery or whole-gland prostate radiation may find focal therapy a more attractive option.
Patients who may not be eligible
- High-Risk or Aggressive tumours
Patients with Gleason scores of 8-10, with grade group 4 or 5 cancers, typically have more aggressive cancers that are more likely to recur. - Widespread Cancer in Multiple Extensive Areas of the Prostate
If cancer is spread outside the capsule of the prostate, focal therapy may leave untreated areas, leading to recurrence. - Very High PSA Levels
Patients with PSA levels significantly above 20 ng/mL are more likely to have extensive disease that cannot be effectively treated with focal therapy alone. - Men Who Want a Single Definitive Treatment
Some patients prefer a one-time treatment option that eliminates cancer with minimal risk of recurrence, and also accept the potential side effects of traditional treatment.
Which Focal Therapy is suitable for you?
HIFU — Best for Posterior Tumours
HIFU (NICE IPG424) uses focused ultrasound waves to treat cancers in the posterior (back) part of the prostate. Your consultant will assess whether your tumour location makes HIFU the right focal therapy option for you.- NICE-approved (IPG424)
- Suitable for posterior and lateral tumours
- Day procedure — most patients go home the same day
Learn more
NanoKnife IRE — Best for Anterior Tumours
NanoKnife IRE (NICE IPG768) is particularly effective for cancers at the front (anterior) of the prostate or near critical structures such as nerves and the urethra. Your consultant will recommend NanoKnife if your tumour location is better suited to this approach.- NICE-approved (IPG768)
- Ideal for anterior tumours and those near nerves
- Day procedure — most patients go home the same day
Learn more
“Well, if you’re deemed suitable for the procedure, it really is a no-brainer.”
Brian Bishop
The Focal Therapy Clinic patient
Learn more about your medical suitability
Meet our World Leading Clinical Specialists
Questions to ask your doctor
| Factor | Focal Therapy (HIFU/NanoKnife) | Surgery | Radiotherapy |
|---|---|---|---|
| Suitable Gleason Score | 6-7 (ISUP 1-3) | All grades | All grades |
| Continence Preservation | 97% (FTC audit, n=265) | 80-95% | 90-95% |
| Sexual Function | 90%+ preserved | 30-70% | 50-70% |
| Recovery | 1-2 weeks | 4-6 weeks | Several weeks |
As Mr Alan Doherty (FRCS(Urol), GMC: 3279241) notes: "Not every patient is suitable for focal therapy, and we're transparent about that. We assess every referral carefully with mpMRI and targeted biopsy before recommending treatment." For detailed information on each treatment, see our HIFU treatment and NanoKnife IRE treatment pages.
| Outcome | Result | Source |
|---|---|---|
| Cancer-free at 1 year | 90% | FTC audit (n=265) |
| Cancer-free at 5 years | 88% | Ganzer et al., 2017 |
| Continence preserved | 97% | FTC audit (n=265) |
| Sexual function preserved | 90%+ | FTC audit (n=265) |
Our patient data shows 85% of men return to work within two weeks. For side-effect details, see our pages on HIFU side effects and NanoKnife side effects.
Follow-Up Schedule:
1. PSA tests every 3 months in the first year.
2. MRI scan at 12 months.
3. Biopsy only if MRI shows something concerning.
4. Regular checks for urinary and sexual health.
This schedule helps detect issues early and manage side effects effectively.
Would you like to know what to expect during each follow-up?
Get Expert Advice & The Latest Research
Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.
Frequently asked questions
- The stage and grade of your prostate cancer (typically Gleason 6–7 or ISUP 1–3).
- Your PSA level (usually ≤20 ng/mL).
- The location and size of the tumour as seen on MRI.
- Your overall health and fitness for treatment.
- Whether the cancer is confined to one area of the prostate and shows no metastasis.
- There are multiple small, well-defined lesions that can be targeted individually.
- The lesions are visible on MRI.
- Your overall cancer risk profile is favourable.
- Overall health and life expectancy.
- Fitness for the procedure rather than age alone.
- Desire to avoid more invasive treatments like surgery.
- MRI Scan: Multiparametric MRI (mpMRI) to visualise the prostate and tumour.
- Prostate Biopsy: Targeted biopsy to confirm presence and grade of cancer.
- PSA Blood Test: Measures PSA levels to assess cancer aggressiveness.
- Additional Tests: PSMA PET or bone scan if metastasis is suspected.
- mpMRI: Shows detailed location, size, and extent of cancer.
- Targeted Biopsy: Confirms presence, grade, and type of cancer.
- Additional Imaging: PSMA PET scan if spread is suspected.
- PSA alone doesn’t determine eligibility.
- Other factors like Gleason score and MRI results are also key.
- PSA slightly above 20 may still qualify if other indicators are favourable.
- Suitable: Gleason 6–7 (ISUP 1–3).
- Less Suitable: Gleason 8–10 (ISUP 4–5), due to aggressiveness and spread risk.
- In select cases with localised disease, it may still be considered alongside other treatments.
- Severe cardiovascular or lung disease.
- Previous pelvic radiotherapy.
- Bleeding disorders.
- Severe inflammatory bowel disease (IBD).
- Tissue condition after radiation.
- Size and location of recurrent cancer.
- Overall health and anaesthetic fitness.
- Radiotherapy to the prostate bed.
- Hormone therapy.
- Salvage cryotherapy or HIFU (in select cases).
- Fitness for anaesthesia (general or spinal).
- Life expectancy (ideally 10+ years).
- Other conditions like heart or lung disease.
- Ability to recover from a short procedure.
- Localised low- to intermediate-risk prostate cancer.
- Some post-treatment cases depending on health and cancer profile.
- Retreatment with focal therapy if cancer recurs.
- Surgery or radiotherapy later if needed.
- Hormone therapy in specific cases.
- Treatment: 60–90 minutes, often day case.
- Recovery: Catheter for 3–5 days; most feel normal within 1–2 weeks.
- Side Effects: Mild discomfort, temporary bleeding, or fatigue.
- Call 0207 036 8870 or email info@thefocaltherapyclinic.co.uk.
- Complete the contact form on the website.
- Your MRI and biopsy results will be reviewed to assess suitability.

At one year after one focal therapy treatment
*Based upon our one-year outcome audit of 265 patients treated at The Focal Therapy Clinic using advanced MRI-ultrasound fusion technology (FTC audit, n=265, Oct 2025)
What to Expect Before, During, and After Focal Therapy
- Pre-treatment imaging (MRI/ultrasound) to pinpoint the cancer
- Blood tests (PSA levels, general health)
- Discussion of anesthesia options (general or spinal)
- Bowel preparation (as advised by your medical team)
What are the side effects of Focal Therapy?
| Symptom | Frequency | Duration |
|---|---|---|
| Increased Urinary Frequency | Common | Usually temporary |
| Mild discomfort in perineum area | Common | 2-3 Days |
| Erectile dysfunction | Rare <5% | Usually temporary |
| Blood in urine or semen | Rare | - |
| Urinary Catheter required | Sometimes | 3-5 Days |
| Risk of incontinence | Rare | - |
| Repeat Treatment | Sometimes | - |

Choosing Between NanoKnife & HIFU: Key Factors
| Benefit | NanoKnife | Hifu |
|---|---|---|
| Best for Tumour Location | Irregularly shaped or near critical structures (nerves, urethra) | Well-defined tumours in specific prostate zones |
| Preservation of Nerves | No heat damage; excellent for preserving erectile function | Low risk, but heat may affect nearby structures |
| Suitability for Recurrent Cancer | Ideal for post-radiation recurrence | For tumours near the base of the prostate |
| Side Effects | Minimal impact on urinary function and sexual health | Low risk of incontinence and erectile dysfunction |
| Treatment risk | Risk of rectal injury at base of prostate | Risk of under treatment at front of prostate |
Reference List
Ahmed HU et al. (2015). Focal therapy for localised prostate cancer: a systematic review of the literature. Nature Reviews Urology.
Ganzer R, Fritsche HM, Brandtner A, et al. (2017). Five-year outcome of HIFU treatment for localised prostate cancer. Urologia Internationalis.
The Focal Therapy Clinic – Prostate Cancer Treatments (Internal Resource).
NHS Resources on Prostate Cancer (Internal/External Resource).
Subscribe to our newsletter
Get expert advice & the latest prostate cancer research - straight to your inbox.






